AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06471608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulatory management
Description: * Chest tube drainage in emergency department (Furhmann drain connected to Heimlich valve), connected to suction system at -5 to -10 cm H2O until bubbling stops~* Follow-up imaging at 4 hours (chest X-ray or low-dose CT scan, depending on management practices in the centers)~  * if the pneumothorax is still very large, or if clinical tolerance is unsatisfactory (dyspnea, unrelieved pain, abnormal vital parameters), the patient should be admitted to hospital~ * if the lung is in the process of reattachment and a minimal detachment persists, and clinical tolerance is good (assessed on vital parameters, with oxygen saturation above 98%, good hemodynamic stability and pain relieved by analgesics), the patient may be discharged home.
Study NCT06471608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Hospitalisation in a hospital department (pulmonology, thoracic surgery, short-stay emergency unit, critical care, according to the usual pathway of the center in which the patient is included).~In-hospital monitoring until complete resolution of pneumothorax and drain removal (average 4-6 days).
Study NCT04886362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Treatment with Ivermectin in the first 7 days from symptoms onset.
Study NCT04886362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with Placebo in the first 7 days from symptoms onset.
Study NCT05672589 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Relaxed Rotational Thromboelastometry
Description: Relaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients. bleed.
Study NCT05672589 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Coagulation Tests
Description: Standard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed.
Study NCT05343091 — intervention group
Intervention type: DEVICE
Intervention: cardiac ultrasound
Description: Cardiac ultrasound with Pocket ultrasound by expert and non expert physician
Study NCT05087121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F)
Description: The Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F) 6-week training course has been derived from existing Cognitive Behavioral Therapy for Insomnia (CBT-I) group therapy protocols. Participants in this intervention will receive psychoeducation on sleep and practice skills standard of CBT-I including, stimulus control techniques, sleep restriction, counter-arousal skills, cognitive restructuring, sleep hygiene, goal setting, and relapse prevention skills. Weekly sessions will include discussions regarding difficulties specific to occupational barriers and how to mitigate the impact of occupational requirements on sleep quality.
Study NCT05087121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Inspire HR Wrist Worn Device (NCT04176926)
Description: The Fitbit Inspire HR wrist worn device will be worn by eligible participants throughout the duration of the intervention and for two weeks following completion of the 6-week intervention to collect objective data on enduring sleep changes. This device is an FDA-registered medical device that is not the object of investigation and is being used on label only to gather data.~501(K) Number: K200948 Device Name: Fitbit ECG App Regulation Number: 870.2345 Classification Product Code: QDA Clinical Trials: NCT04176926
Study NCT06169956 — intervention group
Intervention type: DRUG
Intervention: Neoadjuvant nivolumab in combination with platinum-based chemotherapy
Description: Neoadjuvant treatment of resectable non-small cell lung cancer with nivolumab in combination with chemotherapy according to current summary of product characteristics
Study NCT04255966 — intervention group
Intervention type: DEVICE
Intervention: Plasmafit® Revision Structan®
Description: Plasmafit® Revision Structan® Hip Endoprosthesis Cup
Study NCT05369689 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: As this is a prognosis evaluation study, there are no interventions.
Study NCT05133414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selective left subclavian ansae stimulation
Description: Percutaneous, transarterial approach for target stimulation
Study NCT05061602 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of biomechanics and viscoelastic properties of plantar fascia
Description: The biomechanical and viscoelastic properties of the plantar fascia will be measured with the MyotonPRO device.
Study NCT05285202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active TB case finding with linkage to preventive therapy (ACF/TPT)
Description: ACF/TPT in both intervention arms will consist of TB screening by mobile chest X-ray (with artificial intelligence-based reading, followed by confirmatory sputum testing with Xpert MTB/RIF Ultra for participants with abnormal x-rays), and linkage to preventive therapy for those who are TB-negative and eligible for TPT (limited in April 2024 to those with close TB contact or known HIV infection).
Study NCT05744882 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: coronectony
Description: root canal treatment
Study NCT05744882 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronectony
Description: root canal treatment
Study NCT05744882 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: root canal treatment
Description: root canal treatment
Study NCT05433402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChlorproMAZINE 50 MG
Description: The experimentall group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours) plus choloropromazine 50 mg daily for 6 months
Study NCT05433402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive folinic acid, fluorouracil and oxaliplatin (mFOLFOX6) regimen every 14 days for (6-12 cycles) (6 months) (Day 1: 5-FU IV 400 mg/m2, leucovorin IV 400 mg/m2, oxaliplatin IV 85 mg/m2, 5-FU continuous IV infusion (CIVI) 1200 mg/m2/day x 2 days (over 46-48 hours)
Study NCT05192980 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention NA
Description: Additional blood sampling (not mandatory)
Study NCT05555602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold-air cooling
Description: Cryo 6 works with a compressor system like those in refrigerators and uses ambient air to generate a permanent stream of cold air with a maximum flow to 1000 L/min and a temperature as low as -30°C, depending on the cooling delivery system and the desired cooling level (range 1-9).
Study NCT05290428 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DNA methylation testing
Description: All cervical cytology samples will be tested for PAX1 and JAM3 methylation
Study NCT05982808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CLIF correction
Description: CLIF correction was a novel surgical techqiue of correction of spinal deformtiy with minimal invasive approach
Study NCT05982808 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional correction strategy
Description: conventional correction was the classic surgical techqiue of correction of spinal deformtiy with open posterior approach
Study NCT05640388 — intervention group
Intervention type: OTHER
Intervention: RV3278A - ET0943 cosmetic product
Description: RV3278A - ET0943 study product is applied twice a day on the face during the whole study.
Study NCT05640388 — intervention group
Intervention type: OTHER
Intervention: RV4632A - RY1845 cosmetic product
Description: RV4632A - RY1845 study product must be applied only in case of sensation of skin discomfort
Study NCT04924023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: kaleidoscope application
Description: The children looked into the kaleidoscope and slowly turned it. The researcher asked the children about the colours and shapes seen inside the kaleidoscope. This distraction procedure began immediately before the central venous catheter dressing and continued until it was finished.
Study NCT06480253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helmet Continuous Positive Airway Pressure
Description: Partecipants will be started on Continuous Positive Airway Pressure at 10 cmH2O on inspired fraction of oxygen (FiO2)= 21% with the Helmet interface for a duration of 5 minutes while laying down on a stretcher with head elevated at 60°
Study NCT06480253 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oronasal Mask Continuous Positive Airway Pressure
Description: Partecipants will be started on Continuous Positive Airway Pressure at 10 cmH2O on Inspired fraction of oxygen (FiO2)= 21% with the oronasal mask interface for a duration of 5 minutes while laying down on a stretcher with head elevated at 60°
Study NCT04731142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Huma
Description: Digital remote patient monitoring using blood pressure and blood sugar devices in combination with a smartphone app ('the Huma app'). Participants are provided with home monitoring devices and download the Huma app. Data recorded via the Huma app is self-reported and includes activity data, diet information, blood glucose measurements, blood pressure measurements, weight, and the Diabetes Distress Scale.
Study NCT04731142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video group consultations
Description: Each patient is invited to attend a total of three VGCs during the 12-weeks lasting approximately one hour and 15 minutes each. Each session is facilitated by a Practice Nurse (PN) and consists of 6-10 people with T2DM. The self-reported Huma app (see below) and patient EPR data are used to populate a Discussion Dashboard which is used in each VGC to facilitate discussion. During the first VGC session, patient goals are discussed and adjusted in a group setting with topics relevant to their condition covered by the PN. Between each VGC session, patients spend time working on their goals and continuing to enter self-reported metrics into the Huma app. During the second and third VGC sessions, each patient is discussed, along with their performance against agreed goals.
Study NCT04731142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KNOW Diabetes
Description: Each patient is signed up to a series of educational email campaigns to complement the VGC sessions and provide broader education around diabetes management. Patients receive two emails per week during the 12-week service on a variety of topics.
Study NCT04731142 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Normal primary care service provided to matched control group.
Study NCT04673877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic IV Vancomycin
Description: 1 g of vancomycin will be delivered intravenously over a period of one hour prior to tourniquet inflation.
Study NCT04673877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bier Block
Description: After exsanguination of the limb and elevation of the tourniquet in the prepped and draped patient, Vancomycin will be injected into a superficial vein in the hand, wrist or forearm.
Study NCT04673877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 500 mg diluted in 50 cc normal saline of injection into superficial vein in the hand, wrist or forearm
Study NCT05442073 — intervention group
Intervention type: OTHER
Intervention: PEEP adjustment
Description: adjusting PEEP about 3-5cmH2O (increase or decrease)
Study NCT06187597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Patients received S-1 administration, 70mg/m2 per day, orally on days 1 to 14 and 29 to 42 during radiotherapy.
Study NCT06187597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Patients received S-1 administration, 70mg/m2 per day, orally on days 1 to 14 and 29 to 42 during radiotherapy.
Study NCT06187597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Patients received toripalimab 240 mg every 3 weeks for up to 16 cycles.
Study NCT06187597 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 54 Gy in 27 fractions over 5-6 weeks.
Study NCT06187597 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 54 Gy in 27 fractions over 5-6 weeks.
Study NCT05510622 — intervention group
Intervention type: OTHER
Intervention: Vaginal swab and endometrial biopsy
Description: A vaginal swab (DNA/RNA shield collection tube with swab - Zymo Research, CatNo R1107) and endometrial biopsy (Endobrush® - Lab CCD, Paris, France) will be obtained during 18th - 22nd day of the menstrual cycle.
Study NCT04582669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Triamcinolone 10 mg/mL
Description: Injection of 1 mL intralesional triamcinolone 10 mg/mL in up to 3 anatomic areas.
Study NCT04582669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Triamcinolone 20 mg/mL
Description: Injection of 1 mL intralesional triamcinolone 20 mg/mL in up to 3 anatomic areas.
Study NCT04582669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional Triamcinolone 40 mg/mL
Description: Injection of 1 mL intralesional triamcinolone 40 mg/mL in up to 3 anatomic areas.
Study NCT04582669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of 1 mL sodium chloride 0.9% in up to 3 anatomic areas.
Study NCT06511518 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioural therapy (CBT) is a therapy that can help you manage your problems by changing the way you think and behave.
Study NCT01586429 — intervention group
Intervention type: OTHER
Intervention: Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)
Study NCT05503693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP303 50 μg
Description: AP303 tablet
Study NCT05503693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP303 150 μg
Description: AP303 tablet
Study NCT05503693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP303 300 μg
Description: AP303 tablet
Study NCT05503693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP303 600 μg
Description: AP303 tablet
Study NCT05503693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 50 μg
Description: Placebo tablet
Study NCT05503693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 150 μg
Description: Placebo tablet
Study NCT05503693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 300 μg
Description: Placebo tablet
Study NCT05503693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 600 μg
Description: Placebo tablet
Study NCT05429099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Surgical Planning (VSP)
Description: The 3D reconstruction model, not requiring sterilization, will be sent directly to the SS. Prior to surgery, the SS will prebend a titanium fixation plate to the reconstruction model. Both the surgical cutting guides and titanium plate will be sterilized prior to use in surgery. If the planned resection cannot proceed (possibly due to tumour growth), the surgical team will note the reason for abandonment and conduct a standard FHS. Intraoperatively, the SS will apply the mandibular cutting guide to make the resection, remove the resected component and apply the pre-bent plate. Next, either the fibular or scapular cutting guide is applied to harvest the transplant which is then secured to the plate. The flap is re-vascularized by joining it to blood vessels in the neck.
Study NCT05429099 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free-Hand Surgery
Description: The SS will adopt their standard procedure for the mandibular resection and reconstruction. This typically involves bending a titanium fixation plate, harvesting of the bony flap, and shaping of the segments all intraoperatively based on the SS's judgement.
Study NCT04607681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EDUCATION
Description: WEB BASED EDUCATION
Study NCT05079321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydra-PEG
Description: Zen™ RC scleral lenses (Hydra-PEG coated)
Study NCT05079321 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Uncoated
Description: Zen™ RC scleral lenses (non-coated)
Study NCT05954936 — intervention group
Intervention type: OTHER
Intervention: Risk factor
Description: No therapeutic or diagnostic intervention will be provided; it is an observational study.
Study NCT06308588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given by Infusion
Study NCT06308588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Given by PO
Study NCT05103436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: Electrical nerve stimulation
Study NCT06516874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy for complex presentation (TF-CBT-CP)
Description: This TF-CBT-CP is a short-term intervention to treat outpatients. This will be carried out via videoconference.
Study NCT06516874 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TAU
Description: waiting list, access to pharmacological treatment, and/or non-specialized PTSD psychotherapy sessions.
Study NCT05166850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PICHA7 mHealth program
Description: The PICHA7 mHealth program is first delivered during a health facility visit by a health promoter bedside to a diarrhea patient (adults and child) and their accompanying household members during the time of illness followed by two home visits during the 7-day high risk period for diarrheal disease transmission. The health promoter delivers a pictorial WASH module on how diarrhea can spread, and instructions on handwashing with soap, water treatment, and safe water storage. A diarrhea prevention package is provided containing: a one-month supply of chlorine tablets for water treatment, a soapy water bottle for handwashing, a handwashing station, and a water vessel with a lid and tap to ensure safe water storage. After health facility delivery of the program, patient households receive weekly voice and text messages from the PICHA7 mHealth program over 12 months on the recommended WASH behaviors.
Study NCT05166850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Arm
Description: Standard message given in the Democratic Republic of the Congo to diarrhea patients at health facility discharge on use of oral rehydration solution
Study NCT05166850 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Arm
Description: Standard message given in the Democratic Republic of the Congo to diarrhea patients at health facility discharge on use of oral rehydration solution
Study NCT04991350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal ranibizumab
Description: Intravitreal injection of 0.3 mg/0.05 ml ranibizumab will be performed monthly for 3 months.
Study NCT04991350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab
Description: Intravitreal injection of 1.25 mg/0.05 ml bevacizumab will be performed monthly for 3 months.
Study NCT05112757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone application use
Description: Use of a smartphone application
Study NCT04991038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAISe Device
Description: Thrombectomy using the DAISE device
Study NCT04991038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trevo or Solitaire
Description: Thrombectomy using TREVO or Solitaire device
Study NCT05347745 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: therascreen® KRAS RGQ PCR Kit
Description: Utilize a Clinical Trial Assay, the KRAS Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190172) in order to identify patients with CRC with KRAS G12C mutation positive tumors This will allow the clinical data from the study to be used to determine the drug-device efficacy to support future regulatory submissions for the device-drug combination.
Study NCT06415396 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete Decongestive Therapy
Description: conventional CDT program consisting of MLD, compression bandage, skin care and lymphedema exercises, for a total of 15 sessions, five days a week for three weeks.
Study NCT06415396 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: ESWT was applied to the second group for a total of 5 sessions, 2 sessions in the first two weeks and 1 session in the last week. .
Study NCT06415396 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LLLT
Description: In the third group, LLLT was applied for a total of 9 sessions, 3 sessions per week, in addition to conventional CDT.
Study NCT05532020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCCR (diazoxide choline) extended-release tablets
Description: All participants will be titrated over a four week period to the maintenance dose. Participants will take DCCR daily for up to 52 weeks.